Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070441
Filing Date
2025-05-13
Accepted
2025-05-13 16:31:42
Documents
61
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tpst-20250331.htm   iXBRL 10-Q 1808875
2 EX-31.1 tpst-ex31_1.htm EX-31.1 20577
3 EX-31.2 tpst-ex31_2.htm EX-31.2 20367
4 EX-32.1 tpst-ex32_1.htm EX-32.1 10018
  Complete submission text file 0000950170-25-070441.txt   6435967

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tpst-20250331.xsd EX-101.SCH 909968
64 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20250331_htm.xml XML 851861
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35890 | Film No.: 25940678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)